Kexing Biopharm Obtained IND Approval for Its Self-developed GB05 from U.S. FDA
SHENZHEN, China, Feb. 14, 2025 /PRNewswire/ -- Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1b Inhalation Solution, a self-developed product by...
Ferrero Group reports Consolidated Financial Statements for the 2023/2024 Financial Year
The Ferrero Group continues its growth trajectory with an 8.9% increase in turnover to EUR18.4 billion. Continued innovation across new products and categories including the launch of Nutella Ice Cream in the same year the brand turns 60 years old....
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market...
Illuccix® Approved in the United Kingdom
MELBOURNE, Australia, Feb. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart...
Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China
Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects SHANGHAI, Feb. 7, 2025...
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC Serplulimab has now...
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...
Thailand BOI Approves Investments Worth A Total of US$5 Billion, Including TikTok's Data Hosting Project; Green Lights Revised Incentives for the Bioeconomy
BANGKOK, Jan. 29, 2025 /PRNewswire/ -- The Thailand Board of Investment (BOI) today approved investment privileges for projects worth a combined 170.5 billion baht (ca. US$5 Billion) in value, including a digital infrastructure project by leading...
Korea Zinc Announces EGM Results, Affirming the Important Position the Company Holds in National Key Industry
SEOUL, South Korea, Jan. 24, 2025 /PRNewswire/ -- On January 23, Korea Zinc (KRX:010130) held an extraordinary general meeting (EGM) at Grand Hyatt Seoul to vote on eight agenda items proposed for amendments to the company's articles. Among these,...